Collegium to Present at the 29th Annual Piper Jaff
Post# of 301275
CANTON, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL ) today announced that senior management will participate in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference at 2:30pm ET on Tuesday, November 28, 2017 in New York City.
Abou t Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx ® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza ® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact : Alex Dasalla adasalla@collegiumpharma.com
(0)
(0)